ENTITY
CanSino Biologics

CanSino Biologics (688185 CH)

101
Analysis
Health CareChina
CanSino Biologics Inc. develops and manufactures biological vaccine products. The Company discovers quadrivalence meningococcal conjugate, pneumococcal polysaccharide, and adenovirus vector-based tuberculosis vaccines for human use. CanSino Biologics serves customers worldwide.
more
03 Nov 2024 10:05

A-H Premium Weekly (Nov 1st):Chalco, ZOOMLION, FDZJ, FLAT GROUP, RemeGen, CanSinoBIO

We analyzed A-H premium changes in the past week and highlight A-H premium changes for Chalco, ZOOMLION, FDZJ, FLAT GROUP, RemeGen, CanSinoBIO.

Logo
213 Views
Share
14 Apr 2024 23:25

CanSino Biologics (688185 CH): Limited Downside Is Seen; Meningococcal Vaccines to Drive Growth

​CanSino saw 266% YoY revenue growth in 2023 from meningococcal vaccines, with expectations of 140% YoY increase in 2024 driven by the same...

Logo
607 Views
Share
07 Jan 2024 09:22

China Healthcare Weekly (Jan.5) - WuXi XDC, GLP-1s New Game Rule, Innovent, Cansino, A-Share Outlook

WuXi XDC remains our top pick.We're optimistic about its share price.Game rule of GLP-1 will be different from traditional drugs.Investors should...

Logo
440 Views
Share
23 Oct 2024 08:55

CanSino Biologics (6185.HK/688185.CH) - Breakeven May Arrive Earlier than Expected

​CanSino 24H1 results beat expectation due to strong CDMO revenue/effective cost control/increased MCV demand. PCV13i approval would be faster-than...

Logo
271 Views
Share
13 Oct 2024 10:05

A-H Premium Weekly (Oct 11th):BYD, SMIC, TSINGTAO, Guotai Junan Securities, HAITONG, CanSino

We analyzed A-H premium changes in the past week and highlight A-H premium changes for BYD, SMIC, TSINGTAO, Guotai Junan Securities, HAITONG,...

Logo
317 Views
Share
x